Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
γ-Secretase inhibitor–resistant glioblastoma stem cells require RBPJ to propagate
Xing Fan
Xing Fan
Published June 20, 2016
Citation Information: J Clin Invest. 2016;126(7):2415-2418. https://doi.org/10.1172/JCI88619.
View: Text | PDF
Commentary

γ-Secretase inhibitor–resistant glioblastoma stem cells require RBPJ to propagate

  • Text
  • PDF
Abstract

Targeting glioblastoma stem cells with γ-secretase inhibitors (GSIs) disrupts the Notch pathway and has shown some benefit in both pre-clinical models and in patients during phase I/II clinical trials. However, it is largely unknown why some glioblastoma (GBM) does not respond to GSI treatment. In this issue of the JCI, Xie et al. determined that GSI-resistant brain tumor–initiating cells (BTICs) from GBM express a higher level of the gene RBPJ, which encodes a mediator of canonical Notch signaling, compared to non-BTICs. Knockdown of RBPJ in BTICs decreased propagation in vitro and in vivo by inducing apoptosis. Interestingly, RBPJ was shown to regulate a different transcription program than Notch in BTICs by binding CDK9, thereby affecting Pol II–regulated transcript elongation. Targeting CDK9 or c-MYC, an upstream regulator of RBPJ, with small molecules also decreased BTIC propagation, and prolonged survival in mice bearing orthotopic GBM xenografts. This study not only provides a mechanism for GSI treatment resistance, but also identifies two potential therapeutic strategies to target GSI-resistant BTICs.

Authors

Xing Fan

×

Figure 1

Targeting tumor cells with elevated level Notch activity with γ-secretase inhibitors (GSIs) or shRBPJ.

Options: View larger image (or click on image) Download as PowerPoint
Targeting tumor cells with elevated level Notch activity with γ-secretas...
Tumor cells with elevated levels of Notch activity can be divided into Notch signaling–dependent and –independent classes, which are based on their genetic or epigenetic background. For Notch-dependent tumor cells, GSI treatment can reduce Notch target gene expression and decrease propagation. However, shRPBJ in these same cells will release RBPJ-mediated repression of gene transcription, induce expression of Notch target genes, and increase tumor cell propagation. In contrast, in Notch-independent tumor cells, or GSI-resistant cells, GSI treatment still can block NICD formation and decrease Notch target gene expression. However, GSI treatment has no effect on propagation, because growth of Notch-independent tumor cells depends on genes that are not Notch targets. In this issue, Xie et al. demonstrate that knockdown of RBPJ in Notch-independent cells downregulates expression of genes, including FOXM1, CCNA2, and KRAS, that control brain tumor–initiating cell (BTIC) self-renewal and proliferation, and thereby decreases tumor growth through partnering with CDK9, which regulates elongation of RBPJ target genes. Furthermore, Xie et al. found that RBPJ is regulated by MYC and that blocking MYC expression, upstream of RBPJ, with JQ1 or blocking activity of CDK9 also decreases Notch-independent tumor cell propagation. Solid blue lines indicate results from Xie et al. Solid black lines indicate results from other reports.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts